ARS Pharmaceuticals, Inc.
SPRY
Jodie situation report
ARS Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
- SPRY's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if SPRY's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind SPRY
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMRXAmneal Pharmaceuticals, Inc.competitorMay 15, 2026 ▾
“Additionally, the development of new treatment methods for the diseases we are targeting could render our current or future product candidates non-competitive or obsolete.”
NVSNovartis AGcompetitorMay 15, 2026 ▾
“Additionally, the development of new treatment methods for the diseases we are targeting could render our current or future product candidates non-competitive or obsolete.”
TEVATeva Pharmaceutical Industries LimitedcompetitorMay 15, 2026 ▾
“Additionally, the development of new treatment methods for the diseases we are targeting could render our current or future product candidates non-competitive or obsolete.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
SPRY is currently a Early Follower in the organic co-movement group Healthcare Biotech & REITs. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for SPRY; it is not active in the latest market snapshot.